云南医药产业技术创新效率研究——基于BCC-DEA模型与主成分分析法  

Technological Innovation Efficiency of Pharmaceutical Industry in Yunnan——Based on BCC-DEA Model and Principal Component Analysis

作　　者：党国英 姚含烨 Dang Guoying;Yao Hanye(College of Economics and Management,Southwest Forestry University,Kunming Yunnan 650224,China)

机构地区：[1]西南林业大学经济管理学院,云南昆明650224

出　　处：《西南林业大学学报（社会科学）》2017年第3期73-80,共8页Journal of Southwest Forestry University(Social Sciences)

基　　金：西南林业大学科研启动项目"林业知识产权保护的技术创新效应研究"资助(111606)

摘　　要：医药产业的技术创新效率是影响医疗条件和生活水平的重要因素。采用DEA模型对云南医药产业技术创新效率进行综合评价,借助主成分分析对影响云南医药产业技术创新效率的主要因素进行分析发现:增加研发投入有利于云南医药产业技术创新效率水平提升,企业成长能力对云南省医药产业技术创新效率的作用并不明显,市场集中度对技术创新效率的提升具有正向促进作用,政府支持力度的加强对医药产业技术创新效率的提升具有抑制作用。The technological innovation efficiency of pharmaceutical industry is the important factor that can influence the medical condition and level of life.Firstly,using the DEA model for comprehensive evaluation of medicine industry technology innovation efficiency,and with the help of principal component analysis,the main factors influencing the efficiency of Yunnan medicine industry technology innovation was analyzed,found that the increasing R&D input is advantageous to the Yunnan medicine industry technology innovation efficiency.The scientists and engineers of pharmaceutical industry did not play a proper innovation.Enterprise growth ability on the effect of the Yunnan province medicine industry technology innovation efficiency is not obvious.To promote the efficiency of market concentration on technology innovation has a positive role.Strengthening of the government support to promote the efficiency of technological innovation for the pharmaceutical industry has inhibitory effect.

关 键 词：技术创新效率 医药产业 云南 

分 类 号：F260[经济管理—国民经济]